SAREPTA THERAPEUTICS ($SRPT) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of -$3.42 per share, missing estimates of -$0.97 by $2.45. The company also reported revenue of $744,860,000, beating estimates of $697,022,854 by $47,837,146.
You can see Quiver Quantitative's $SRPT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SAREPTA THERAPEUTICS Insider Trading Activity
SAREPTA THERAPEUTICS insiders have traded $SRPT stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $SRPT stock by insiders over the last 6 months:
- HANS LENNART RUDOLF WIGZELL sold 10,500 shares for an estimated $1,310,820
- CLAUDE NICAISE sold 2,491 shares for an estimated $248,203
- KATHRYN JEAN BOOR sold 1,636 shares for an estimated $205,399
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
SAREPTA THERAPEUTICS Hedge Fund Activity
We have seen 202 institutional investors add shares of SAREPTA THERAPEUTICS stock to their portfolio, and 252 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS added 2,437,855 shares (+38.9%) to their portfolio in Q4 2024, for an estimated $296,418,789
- BANK OF NEW YORK MELLON CORP removed 1,354,401 shares (-63.1%) from their portfolio in Q1 2025, for an estimated $86,437,871
- BLACKROCK, INC. removed 1,285,118 shares (-11.5%) from their portfolio in Q1 2025, for an estimated $82,016,230
- UBS GROUP AG added 1,115,826 shares (+306.4%) to their portfolio in Q4 2024, for an estimated $135,673,283
- ECOR1 CAPITAL, LLC added 770,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $93,624,300
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 753,845 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $91,660,013
- WELLINGTON MANAGEMENT GROUP LLP removed 657,842 shares (-24.1%) from their portfolio in Q4 2024, for an estimated $79,987,008
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SAREPTA THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $SRPT in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BMO Capital issued a "Outperform" rating on 12/02/2024
- Piper Sandler issued a "Overweight" rating on 11/27/2024
- Needham issued a "Buy" rating on 11/27/2024
To track analyst ratings and price targets for SAREPTA THERAPEUTICS, check out Quiver Quantitative's $SRPT forecast page.
SAREPTA THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $SRPT recently. We have seen 3 analysts offer price targets for $SRPT in the last 6 months, with a median target of $182.0.
Here are some recent targets:
- An analyst from Piper Sandler set a target price of $110.0 on 04/21/2025
- Gil Blum from Needham set a target price of $202.0 on 11/27/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
